Navigation Links
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Date:9/24/2008

e (SAD) Study in Healthy Volunteers (Poster #1871): ITMN-191 was safe and well tolerated when given as a single dose to healthy adults in a range of doses from 2mg to 1600mg. Adverse events were generally mild and transient and were similar between treatment groups, with the exception of a higher frequency of mild and transient diarrhea and abdominal pain in the ITMN-191 group at the highest tested dose (1600mg). The pharmacokinetics of ITMN-191 were linear over the dose range of 100mg to 800mg. Co-administration of ITMN-191 with food increased the expected trough and AUC by 40-50% compared with administration of ITMN-191 without food. This "food effect" enabled InterMune and Roche to explore a lower range of doses of ITMN-191 in subsequent clinical studies than was previously planned.

-- A Phase 1b Monotherapy Multiple-Ascending-Dose (MAD) Study in HCV Genotype 1 Patients (Poster #1847): ITMN-191 was administered as mono-therapy for 14 days to four cohorts of treatment-naive patients infected with HCV genotype 1. Multiple ascending doses were examined up to a total daily dose of 600mg. The safety and tolerability of ITMN-191 were excellent. Adverse events were generally mild and transient, with no evidence of clinically significant laboratory abnormalities or ECG changes. When ITMN-191 was administered every eight or twelve hours, viral kinetic results were very competitive with those of other direct antiviral compounds studied in similar experiments.

The MAD study also included one exploratory cohort of ITMN-191 given as mono-therapy for 14 days to strictly defined non-responders: HCV genotype 1 patients who had failed to achieve a 2.0 log10 reduction in HCV RNA with prior standard-of-care treatment, or who still had detectable HCV RNA after 24 weeks of treatment. At the one dose studied of 300mg given every 12 hours, ITMN-191 delivered a median reduction of HCV RNA at study day 14 of 2.5 log10. The results from this initial exploratory cohort in non
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
4. InterMune to Present at BMO Healthcare Conference
5. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
6. InterMune to Present at Jefferies Healthcare Conference
7. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
8. InterMune to Present at Citigroup Healthcare Conference
9. InterMune to Present at Bank of America Health Care Conference
10. InterMune to Present at Deutsche Bank Health Care Conference
11. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 Clinverse, Inc. , ... clinical trials, today announced it will be exhibiting ... #2000) in Boston, June 24-26, 2013. Clinverse’s ... only fully configurable, cloud-based clinical financial lifecycle system. ... within Clinverse’s eClinical Commerce Network, automates site contract ...
(Date:6/19/2013)... 2013   NineSigma , Inc., of ... its launch, NineSights.com is now the innovation ... the worldwide community of innovators. From technology ... experts, NineSights stands out for its large community of ... technical disciplines, all vetted by NineSigma. The community is ...
(Date:6/19/2013)... , June 19, 2013 ... Book Bureau presents Innovative Drug ... Formulation Technology Licensing Opportunities for ... ) There are ... controlled release drugs approved all ...
(Date:6/19/2013)... Washington (PRWEB) June 18, 2013 A ... complex materials, costs and other trends will highlight technical ... Monterey, California this fall. In its 33rd year, the ... includes an exhibition of key suppliers, approximately 100 technical ... SPIE, the international society for optics and photonics ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3
... today announced that management will present at the following,investor conferences ... Conference New York Palace Hotel Wednesday, November 12, ... Annual Healthcare Conference The St. Regis Hotel, New York ... The presentations will be audio webcast live and available for ...
... SAN DIEGO, Nov. 5 Vical Incorporated (Nasdaq:,VICL) today reported ... the third quarter of 2008 were $0.8 million, compared,with revenues ... net loss,for the third quarter of 2008 was $9.8 million ... share for the third quarter of 2007., Revenues for ...
... TUSTIN, Calif., Nov. 4 ( http://www.amdl.com ),AMDL, Inc. ... Executive,Officer and Director, Gary L. Dreher, has retired at ... been a member of the Company,s leadership,team and a ... wishes to,Mr. Dreher on his retirement., About AMDL:, ...
Cached Biology Technology:Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 6AMDL, Inc.'s President & CEO Mr. Gary Dreher Retires 2
(Date:6/18/2013)... is estimated that between 5% and 10% of breast ... to say that these tumours are attributable to inherited ... or BRCA2. In patients with these mutations, PARP inhibitors, ... results that make them a new option for personalised ... latest studies indicate that a fraction of these patients ...
(Date:6/18/2013)... University of Adelaide shows that weight gain and increased ... linked to a higher IQ at early school age. , The ... analysed data from more than 13,800 children who were born full-term. ... , show that babies who put on 40% of their birthweight ... by the time they were six years of age, compared with ...
(Date:6/17/2013)... with severe brain infections in Vietnam. Further research is ... the symptoms of disease. , The virus was found ... with severe brain infections in the study, corresponding to ... patients with non-infectious brain disorders that were tested. , ... often fatal and patients who do survive, often young ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2IQ link to baby's weight gain in first month 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3
... With its vast 1.5 million acres of mangrove swamps, ... famous river of grass--be affected by the Gulf oil ... any oil entered the Loop Current or reached the ... and to study the effects of the spill on ...
... 2010 How well do you understand life in your own ... where humans aren,t visitors; they are an integral component, like trees ... half of the Earth,s people live in cities and the amount ... area of Ohio, shouldn,t our sciences thrive in the city? ...
... available in Spanish . Beautiful ... havens created as an efficient, practical, environmentally friendly, and ... young bees. The pesticide-free pastures could be simple ... tend, according to U.S. Department of Agriculture (USDA) entomologist ...
Cached Biology News:Gulf oil spill: NSF funds research on impacts to Florida Everglades 2The real urban jungle 2Bee pastures may help pollinators prosper 2
... Mini thermal cycler is a compact instrument for ... ml tubes, 12 x 0.5 ml tubes, or ... uses a thumbwheel to adjust height and pressure ... Peltier heat pumps provide excellent thermal performance, and ...
... Immunophosphatase Secondary Detection System is intended for ... Primary Antibody reagents, which contain rat and ... antigens by light microscopy in paraffin-embedded tissues. ... may also be used with other rat ...
... of the mitochondrial transmembrane potential ... intracellular events that occur following ... Apoptosis Detection Kit utilizes a ... as a mitochondrial activity marker. ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: